Research Ethics and Compliance: What Every Peptide Researcher Needs To Know
Research Standards · 5 min read · syntheralab.com
Peptide research operates within a specific and evolving regulatory landscape. Understanding the legal, ethical, and practical dimensions of working with research-grade peptides is not optional — it is foundational to conducting responsible science. This post is designed to provide researchers with a clear-eyed overview of the current environment.
The research-only designation
Research-grade peptides are manufactured and sold strictly for laboratory and in-vitro research purposes. They are not approved for human consumption, clinical use, or diagnostic application. This designation is not merely a legal formality — it reflects the genuine state of human evidence for most research peptides. Preclinical evidence, even when compelling, does not translate directly to clinical practice, and researchers must operate within this boundary.
FDA regulatory context
The FDA's regulatory approach to research peptides has evolved significantly. BPC-157 was designated a Category 2 bulk drug substance in 2023, meaning it cannot be legally compounded for human use by 503A or 503B pharmacies. An enforcement wave beginning in late 2024 and accelerating through April-May 2025 resulted in the shutdown of multiple vendors. Researchers should be aware that the regulatory environment continues to evolve and that working with compounds sold outside FDA-approved channels carries responsibility for understanding applicable regulations.
WADA and anti-doping context
BPC-157 and TB-500 are both prohibited by the World Anti-Doping Agency (WADA) for use in sport. Researchers working with athletic populations or in sports medicine contexts should be aware of this status. The WADA 2025 International Standard Prohibited List specifically includes peptide hormones and related substances. This prohibition applies to use in competition and out-of-competition contexts.
Institutional and ethical obligations
Researchers using peptides in laboratory settings must comply with all applicable institutional review board (IRB) protocols, institutional biosafety requirements, and applicable federal and state regulations. Animal studies involving peptides must comply with IACUC guidelines. Proper documentation, compound storage per manufacturer specifications, and waste disposal according to institutional protocols are non-negotiable components of responsible peptide research.
Synthera Labs' compliance commitment
Synthera Labs sells exclusively for in-vitro laboratory research purposes. All purchases are subject to our Terms of Service, which require buyers to confirm their understanding of the research-only nature of our products. We maintain this standard not merely as a legal requirement but as a genuine commitment to responsible science. Research integrity requires compound integrity, ethical use, and full transparency.
Research Sources
Vasireddi et al., AJSM (2025): BPC-157 lacks FDA approval and its use is banned in professional sports, yet it is increasingly used by clinicians and athletes, highlighting the importance of regulatory awareness.
WADA 2025 Prohibited List: BPC-157 and TB-500 remain on the World Anti-Doping Agency prohibited substance list for both in- and out-of-competition use.
FDA Category 2 Designation (2023): BPC-157 cannot be legally compounded by 503A or 503B pharmacies for human use under the FDA's Category 2 bulk drug substance classification.
→ Synthera Labs is committed to transparent, responsible distribution for research purposes only. Review our Terms of Service at syntheralab.com.
